Spark Therapeutics Inc (ONCE) Expected to Post Earnings of -$1.10 Per Share

Equities analysts expect that Spark Therapeutics Inc (NASDAQ:ONCE) will announce ($1.10) earnings per share for the current quarter, according to Zacks. Five analysts have issued estimates for Spark Therapeutics’ earnings. The highest EPS estimate is ($0.70) and the lowest is ($1.38). Spark Therapeutics reported earnings of ($1.25) per share in the same quarter last year, which suggests a positive year over year growth rate of 12%. The firm is scheduled to issue its next earnings results on Tuesday, May 21st.

According to Zacks, analysts expect that Spark Therapeutics will report full year earnings of ($4.31) per share for the current fiscal year, with EPS estimates ranging from ($5.64) to ($1.69). For the next fiscal year, analysts expect that the company will post earnings of ($4.12) per share, with EPS estimates ranging from ($5.65) to ($2.15). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Spark Therapeutics.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Tuesday, February 19th. The biotechnology company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.89). Spark Therapeutics had a negative return on equity of 16.68% and a negative net margin of 124.33%. The company had revenue of $13.15 million for the quarter, compared to the consensus estimate of $26.76 million. During the same period in the prior year, the company earned ($1.63) EPS. The firm’s revenue was up 47.9% compared to the same quarter last year.

Several brokerages have recently issued reports on ONCE. Zacks Investment Research lowered shares of Spark Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, April 24th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $80.00 target price on shares of Spark Therapeutics in a research note on Sunday, February 17th. SunTrust Banks lowered shares of Spark Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, February 25th. Mizuho lowered shares of Spark Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, February 25th. Finally, Barclays lowered shares of Spark Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $74.00 to $115.00 in a research note on Monday, March 25th. Eighteen research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $78.45.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Lombard Odier Asset Management USA Corp bought a new position in Spark Therapeutics during the first quarter worth $1,708,000. Longfellow Investment Management Co. LLC bought a new position in Spark Therapeutics during the first quarter worth $854,000. Twin Securities Inc. bought a new position in Spark Therapeutics during the first quarter worth $7,402,000. Schonfeld Strategic Advisors LLC bought a new position in Spark Therapeutics during the first quarter worth $558,000. Finally, Morgan Stanley boosted its position in Spark Therapeutics by 15.9% during the first quarter. Morgan Stanley now owns 230,560 shares of the biotechnology company’s stock worth $26,255,000 after purchasing an additional 31,694 shares during the period.

Shares of NASDAQ ONCE traded down $0.82 during mid-day trading on Thursday, hitting $107.64. The company’s stock had a trading volume of 342,224 shares, compared to its average volume of 458,204. The firm has a market capitalization of $4.13 billion, a PE ratio of -51.01 and a beta of 2.48. The company has a current ratio of 5.94, a quick ratio of 8.68 and a debt-to-equity ratio of 0.18. Spark Therapeutics has a one year low of $34.53 and a one year high of $114.20.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

See Also: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.